- US11753413utility2023Substituted Pyrrolo[2,1-f][1,2,4]triazine Compounds as JAK2 V617F Inhibitors0 cites
- US11753406utility2023Salts of a PD-1/PD-L1 Inhibitor0 cites
- US11738026utility2023Combination Therapy Comprising an ALK2 Inhibitor and a JAK2 Inhibitor0 cites
- US11739102utility2023Fused Pyrimidine Compounds as KRAS Inhibitors0 cites
- US11731958utility2023Carboxamide Compounds and Uses Thereof0 cites
- US11723899utility2023ALK2 Inhibitors for the Treatment of Anemia0 cites
- US11718605utility2023Heterocyclic Compounds as Immunomodulators0 cites
- US11713317utility2023Tricyclic Heterocyclic Compounds as Sting Activators0 cites
- US11691971utility2023Naphthyridinone Compounds as JAK2 V617F Inhibitors0 cites
- US11685731utility2023Processes of Preparing a JAK1 Inhibitor0 cites
- US11673883utility2023Heterocyclic Compounds as Immunomodulators0 cites
- US11673894utility2023Imidazopyrimidines and Triazolopyrimidines as A2A / A2B Inhibitors0 cites
- US11661422utility2023Tricyclic Urea Compounds as JAK2 V617F Inhibitors0 cites
- US11628162utility2023Methods of Treating Cancer with an FGFR Inhibitor0 cites
- US11624751utility2023Biomarkers for Vitiligo0 cites
- US11613536utility2023Heterocyclic Compounds as Immunomodulators0 cites
- US11607416utility2023Bicyclic Heterocycles as FGFR Inhibitors0 cites
- US11608337utility2023Heterocyclic Compounds as Immunomodulators0 cites
- US11602536utility2023Topical Treatment of Vitiligo by a JAK Inhibitor0 cites
- US11596632utility2023JAK1 Pathway Inhibitors for the Treatment of Gastrointestinal Disease0 cites